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Abstract 
6-(4-Aminophenyl)-4,5-dihydro-3(2H)-pyridazinone moiety  is a vital structural part of many cardio-active 
pyridazinone derivatives which are either in clinical use or have been tested in clinical trials. These 
include imazodan, CI-930, pimobendan, indolidan, levosimendan, SK&F-93741, Y-590, meribendan, 
NSP-804, NSP-805, bemoradan, senazodan, amipizone, prinoxodan, SKF 95654, siguazodan and KF 
15232. This article briefly reviews relevant literature on various reports on the synthesis and use of this 
moiety for development of cardio-active agents. 
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Cardiovascular disease is a major public health 
problem worldwide, even in the United States of 
America, and it accounts for approximately 30 % 
of all deaths [1]. Cardiovascular disease has also 
been considered to be the major cause of death 
in the Kingdom of Saudi Arabia [2]. Due to 
increasing prevalence of cardiovascular disease 
in children, researchers have recommended the 
establishment of well-equipped hospitals to for 
the care of children with cardiovascular disease 
in developing countries as well as in Kingdom of 
Saudi Arabia [3]. Studies have also revealed that 
there is a need for more research in the field of 
cardiovascular disease in developing countries 
because of the likelihood of prevalence of 
cardiovascular disease in all age groups in these 
countries [4,5]. 
 
There are many cardio-active derivatives of 6-(4-
aminophenyl)-4,5-dihydro-3(2H)-pyridazinone 
containing 6-(4-aminophenyl)-4,5-dihydro-3(2H)-
pyridazinone moiety (1) as their vital structural 
component. These derivatives are either in 
clinical use or have been tested in clinical trials. 
They include imazodan [6,7]; CI-930 [7,8]; 
pimobendan [7,9]; indolidan [7,10]; levosimendan 
[7,11]; SK&F-93741 [7,12]; Y-590 [7,13]; 
meribendan [14]; NSP-804 [15]; NSP-805 [15]; 
bemoradan [16,17]; senazodan [18]; amipizone 
[7,17]; prinoxodan [19]; SKF 95654 [20]; 
siguazodan [21] and KF 15232 [21]. 
 
Some reviews on pyridazinone derivatives have 
been published [22-25]. However, these reviews 
are directed towards the general chemistry and 
general biological activities of diverse pyridazine 
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derivatives. None of these articles focused on the 
use of any specific chemical moiety for the 
development of cardio-active agents. 
 
The current review gives an insight on the 
potential of 6-(4-aminophenyl)-4,5-dihydro-3(2H)-
pyridazinone moiety for the development of 
cardio-active agents, and briefly discusses 
relevant literature related to the synthesis and 
use of this chemical for the preparation of cardio-
active agents. Accordingly, literature references 
wherein 6-(4-aminophenyl)-4,5-dihydro-3(2H)-
pyridazinone moiety was not  synthesized and/or 
not used for the preparation of cardio-active 
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Figure 1: Some pyridazinone derivatives 
 
6-(4-AMINOPHENYL)-4,5-DIHYDRO-3(2H)-




pyridazinone (1) was first reported in 1967 by 
Gerhard and August [26]. Gerhard and August 
also reported that this compound is associated 
with anti-inflammatory and sustained blood 







Curran and Ross [28] prepared and tested a 
series of 6-phenyl-4,5-dihydro-3(2H)-
pyridazinones. They concluded that the potent 
and most active hypotensive agents (2) in 
normotensive rats were derivatives with 
acetamido and cyano groups in the para or meta 
position of the benzene ring, combined with 5-







R1 = NHCOCH3 or CN; R2 = CH3 R3 = H
2  
 
Thyes et al [29] prepared 6-Aryl-4,5-dihydro-
3(2H)-pyridazinones which exhibited 
aggregation-inhibiting activity on human platelets 
in vitro and on rat platelets ex vivo, as well as a 
hypotensive action on rats. The strongest 
pharmacological effects were found with 
dihydropyridazinones that have R = 
chloroalkanoyl substituent, together with a methyl 
group in the 5-position (3). The hypotensive 
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actions of these compounds were 40 times 








R = chloroalkanoyl substituent
3  
 
These authors further demonstrated that the 
para-substituted compounds had a strong 
inhibiting effect on collagen-induced and ADP-
induced aggregation of human platelets. It is 
known that platelet aggregation plays an 
important role in the pathogenesis of 
cardiovascular disease [30]. 
 
The in vitro human platelet aggregation and the 
ex vivo rat platelet aggregation-inhibiting 
activities of 6-aryl-4,5-dihydropyridazinones (4) 
with R1 = R2 = R4 = Me or H; and R3 = amine 
containing, groups were correlated with the van 
der Waals volume (Vw) of R3 by Gupta et al [31]. 
Their results suggested that the size of the 
substituent on the aryl group plays an important 
role in the inhibition of platelet aggregation in this 
series of compounds. Based on the correlating 
equations obtained, it was further suggested that 
the inhibition of platelet aggregation most likely 
involved hydrophobic interaction. A moderate 
correlation existed between the hypotensive 
activity of these drugs in rats and Vw, indicating 
that hypotensive activity also was partly affected 
by the size of the substituent on the aryl group. 
Although it was assumed that hydrophobic 
interactions also played some role in the 
hypotensive action, it was argued, based on the 
results, that platelet aggregation inhibition and 









R1 = R2 = R4 = Me or H; R 3 = amine containing groups
4  
 
A series of 4,5-dihydro-6-[4-(1H-imidazol-1-
yl)phenyl]-3(2H)-pyridazinones and related 
compounds were synthesized and evaluated for 
positive inotropic activity by Sircar et al [32]. Most 
members of this series produced dose-related 
increases in myocardial contractility that were 
associated with relative minor increase in heart 
rate and decrease in systemic arterial blood 
pressure. Among the synthesized compounds 
(5), the one with R = H (CI-914) and R = Methyl 
(CI-930) were more potent than amrinone and 
milrinone, respectively. It was also postulated 
that the positive inotropic effect of these 
compounds was due to the inhibition of cardiac 
phosphodiesterase fraction III, rather than the 





















R = H (CI-914); Methyl (CI-930)
5  
 
Okushima et al [33] reported pyridazinone 
derivatives with cardiac activity. These 
pyridazinones, with R = H and Me; R1 = 4-pyridyl, 
2-pyridyl, 2-pyrimidyl and 4-quinolyl, were 
evaluated for inotropic activities in vitro and for 
cardio-hemodynamic effects in vivo. The 
hydrochloride salts of compound (6) with R = H 
(MCI-154) or Me and R1 = 4-pyridyl showed 
extremely potent positive inotropic and 









R = H (MCI-154) or Me; R 1= 4-pyridyl
6  
 
Sircar et al investigated the structure-activity 
relationships of a series of 4,5-dihydro-6-[4-(1H-
imidazol-1-yl)phenyl]-3-(2H)-pyridazinones (7) 
with R = H, Me, CH2Ph, CH2CH2OH, 
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CH2CH2OAc; R1 = H, Me, NH2, CONH2; and R2 = 
H, Me, Et; R3 = H, Me, SH, SMe, SOMe, Et, for 
their in vivo inhibition of different forms of cyclic 
nucleotide phosphodiesterase (PDE) isolated 
from guinea pig ventricular muscle [34]. With few 
exceptions, these 4,5-dihydropyridazinones were 
potent inhibitors of cardiac type III 
phosphodiesterase. The most selective PDE III 
inhibitor was CI-930 (R = R1 = R3 = H, R2 = Me) 












Slater et al [35] reported the design and 
synthesis of a series of combined vasodilator-β-
adrenoceptor antagonists based on 6-
arylpyridazinones, and evaluated them as 
vasodilator-β-adrenoceptor antagonists and 
potential antihypertensive agents. Many of the 
synthesized compounds showed high level of 
intrinsic sympathomimetic activities (ISA) and 
relatively short durations of action. Di-substitution 
in the 2,3-positions or in the 4-position of the 
aryloxy ring produced compounds with low ISA 
levels and, in some cases, improved duration of 
action. The 5-methylpyridazinone derivatives 
displayed more antihypertensive activity than 
their 5-H homologs. The compound, SK&F 












Benzodioxane pyridazinones (8) and 
benzodioxane dihydropyridazinone (9) have 
been reported as antihypertensive agents by 
Stefano et al [36]. Derivatives with Z = 1,4-di-
substituted piperazine showed good hypotensive 


















Alfred et al [37] have reported 4,5-dihydro-6-(1H-
indol-5-yl)-pyridazin-3(2H)-ones and related 
compounds with positive inotropic activities. Most 
of these compounds produced increases in 
myocardial contractility with little effects on heart 
rate and blood pressure. The cardiotonic effect of 
compound (10) was at least 2-fold higher than 
that of pimobendan following oral administration. 
It has been suggested that, for optimal 
cardiotonic activity within this class of indole 
derivatives, a heterocyclic aromatic ring in 
position 2, a hydrogen or a Me group in position 
3 and a dihydropyridazinone ring system in 













ones have been synthesized and their PDE III 
inhibitory, inotropic and vasodilator potencies 
compared with those of their normethyl and their 
bicyclic 4,5-dihydro-6-phenylpyridazinone 
analogues by Bakewell et al [38]. The study 
revealed that the structure-activity relationships 
of the tricyclic pyridazinones differ from those of 
bicyclic pyridazinones mainly in respect of the 
effect produced by introducing a methyl group in 
the pyridazinone ring. Introduction of a 5-methyl 
group has been widely reported to lead to 
compounds of significantly greater potencies in 
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the 4,5-dihydro-6-phenylpyridazin-3(2H)-ones. 
On the other hand, the tricyclic 4a-
methylpyridazinones showed similar levels of 
inotropic, vasodilator and PDE III inhibitory 
potencies to their normethyl analogues. In this 
series of compounds, the tricyclic 4a-
methylpyridazinones (11) with R = cyano, 
CONH2, NH2, NHAc, or OMe, and n = 1,2, …., 










R = cyano, CONH2, NH2, NHAc, OMe, n = 1,2, ….
 
Jiang and Sun [39] synthesized 6-(4-substituted 
phenyl)-4,5-dihydro-3(2H)-pyridazinones and 
demonstrated that compound (12) was a good 
inhibitor of platelet aggregation in rats. 
Preliminary pharmacological tests of the other 
compounds revealed that they inhibited ADP-








Lee et al [40] have reported potential 
antihypertensive properties of 8-methyl 
derivatives of 6-(1,4,5,6-tetrahydro-6-
oxopyridazin-3-yl)-1,2,3,4-tetrahydro-1-oxo-β-
carboline. In vitro studies revealed that 
compound (13) exhibited particularly potent and 
long lasting hypotensive activity. Molecular 
modeling also revealed that this compound (13) 
met all the stipulations of 5-point model required 











A series of 6-[4-(amino)phenyl]-4,5-
dihydropyridazin-3(2H)-ones (14) derivatives with 
R = H, Me; R1 = R2 = alkyl; R1R2 = piperazinyl, 
piperidinyl, and related compounds have been 
evaluated as inhibitors of cardiac cAMP 
phosphodiesterase (cAMP PDE) by Abou-Zeid et 
al [41]. However, none of the tested compounds 











Abou-Zeid et al [42] have also reported synthesis 
of positive inotropic 6-substituted 4,5-
dihydropyridazin-3(2H)-ones, for example 
compound  (15) with Z = O, S; R = H, OH, Me; 
R1 = H, Me; R2 = R3 = H, and alkyl; and a ring 
between R2 and R3. An example of these 



















The synthesis and platelet aggregation-inhibitory 
activities of 6-(4-substituted acylamidophenyl)-
4,5-dihydro-3(2H)-pyridazinones and 6-(4-
substituted acylaminophenyl)-4,5-dihydro-3(2H)-
pyridazonones have been described by Liu et al 
[43,44]. Preliminary pharmacological tests 
revealed that all the synthesized compounds 
inhibited appreciable ADP-induced platelet 
aggregation activities in rabbits. Liu et al [45] 
have further reported synthesis of 6-(4-
substituted acylaminophenyl)-4,5-dihydro-3(2H)-
pyridazinones and their inhibitory actions on 
platelet aggregation. These compounds were 
synthesized based on structure-activity 
relationships of anti-platelet aggregation of 
dihydropyridazinones. The synthesized 
compounds showed different levels of inhibitory 
activities on ADP induced-platelet aggregation. 
Synthesis of 6-(4-(substituted amino) phenyl)-
4,5-dihydropyridazin-3(2H)-ones as potential 
positive inotropic agents has been described by 
Abou-Zeid et al [46]. Some of the synthesized 
compounds exhibited good positive inotropic 
effects. 
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The synthesis and anti-platelet aggregation 
activities of 6-(4-substituted acylaminophenyl)-
4,5-dihydro-3(2H)-pyridazinones have been 
reported by Liu et al [47]. These compounds 
appreciably inhibited ADP-induced platelet 
aggregation, with some having more potencies 
than the standard compound, CI-930. Zhao et al 
[48] have reported synthesis of analogues of 
pyridazinones and their inhibition of platelet 
aggregation, with evidence of their ADP-induced 
platelet-inhibitory activities. 
 
Zhao and Liu [49] have reported synthesis of 6-
substituted acylpiperazinyl phenyl dihydro 
pyridazinones and their inhibition of platelet 
aggregation. Preliminary in vitro tests showed 
that all the compounds were effective against 
platelet aggregation induced by ADP. 
 




1(2H)-phthalazinones have been reported by 
Demirayak et al [50]. The most significant 












Demirayak et al [51] have also reported some 
pyrrole-substituted aryl pyridazinones, for 
example compound (18), and demonstrated that 













pyridazinones have been synthesized prepared 
as anti-thrombotic agents by Ren et al [52]. 
Preliminary in vitro tests revealed that all the 
synthesized compounds were active against 
platelet aggregation induced by ADP.  
 
Synthesis and cardiovascular activities of 6-(4- 
aminophenyl)-2,3,4,5-tetrahydropyridazine-3-one  
derivatives have been studied by Dong et al [53]. 
Although these compounds possessed strong 
inotropic activities, they had little effect on the 
right atria of the rat in vitro. Wang et al. [54] 
synthesized series of 6-phenyl-4,5-dihydro-
3(2H)-pyridazinones and studied their cardiotonic 
activities on isolated perfused toad heart, relative 
to levosimendan. From the series, compound 












Three series of pyridazinones were designed as 
vasorelaxant agents using three dimensional 
pharmacophore developed with catalyst software 
by Khaled et al [55]. Several compounds with 
higher fit scores to the developed 
pharmacophore were synthesized, for example, 
6-(3-ethoxycarbonyl-4-oxo-1,4-dihydroquinolin-6-
yl)-5-substituted-4,5-dihydro-3(2H)-pyridazinones 
(20) and 6-[4-(2,6-disubstituted quinolin-4-
ylamino)-2-substituted phenyl]-5-substituted-4,5-
dihydropyridazin-3(2H)-ones (21). The 
vasodilator activities of the newly synthesized 
compounds were examined on isolated main 
pulmonary rabbit arteries. Some of the tested 
compounds showed moderate vasorelaxant 











The anti-platelet aggregation activities of 6-(4-
substituted acetamido phenyl)-4,5-dihydro-3(2H)-
pyridazinones derived from different piperazine 
groups have been studied by Xu et al [56]. All the 
synthesized compounds had potent anti-platelet 
aggregation activities. It was also found that anti-
aggregation activity was influenced by the carbon 
chain   length   of   the   4-substituted   piperazine 
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group. Sun et al [57] synthesized and 
demonstrated anti-platelet aggregative activities 
of 6-(4-substituted acetamidophenyl)-4,5-
dihydro-3(2H)-pyridazinones bearing different 
heterocyclic groups. However stereospecific 
blockage and hydrophilicity of different 
heterocylic groups had impacts on the anti-
platelet aggregative activities of these 
compounds. 
 
Wang et al [21] has designed, synthesized and 
studied the structure-activity relationships of 6-
phenyl-4,5-dihydro-3(2H)-pyridazinone deriva-
tives with respect to their cardiotonic properties. 
Among these compounds, 2,3-dichloro-N-(4-(4-
methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-
yl)phenyl) benzamide (22), 4-amino-3-methyl-N-
(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-
yl)phenyl) benzamide (23), 3-methyl-4-nitro-N-(4-
(6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl) 
benzamide (24) and 4-amino-3-methyl-N-(4-(6-
oxo-1,4,5,6-tetrahydropyridazin-3-yl) phenyl) 
benzamide (25) exhibited cardiotonic activities 
which were comparable to that of levosimendan. 
 
Cai et al [58] reported anti-platelet aggregation 
activities of N-[4-(1, 4, 5, 6-tetrahydro-6-oxo-3- 
pyridazinyl) phenyl] acetamides. The in vitro 
activities of several of the derivatives were higher 
than that of MCI-154 [4,5-dihydro-6-[4-(4-
pyridinylamino) phenyl]-3(2H)-pyridazinone 
hydrochloride]. It was also found that 
stereospecific blocking and hydrophilicity of 
different secondary amino groups in the target 
compounds affected their anti-platelet 
aggregation activities. 
 
Chai et al [59] have reported synthesis and 
potent anti-platelet aggregation activities of 6-[4-
(substituted aminoacetamidophenyl)]-4,5-
dihydro-3(2H)-pyridazinones. It was also 
observed that the anti-platelet aggregation 
activities of the compounds were enhanced by 
introduction of different substituted amino groups 
enhanced. Thota et al [60] synthesized and 
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activities of a series of 6-(4-(substituted amino) 
phenyl)-4,5-dihydro-3(2H)-pyridazinones. The 
compounds (26) and (27) displayed two times 
more platelet aggregation-inhibitory effects than 


















Amin et al [61] successfully synthesized new 4,5-
3(2H)-pyridazinone derivatives with the general 
formula (28), where R = alkyl, alkylamine, 
alkanoylamine or alkoxy group; R1 = alkyl, acetyl, 
COOEt, CN; and RR1 = five membered 
heterocycle. The cardiotonic, hypotensive, and 
platelet-aggregation inhibition activities were also 
investigated. Results from in vitro studies of their 
positive inotropic effects on isolated rabbit heart 
revealed that twelve of the compounds exhibited 
higher effective responses than digoxin, while 
nine compounds were comparable to digoxin in 
their responses. However eight of the 










Cardiovascular disease has become the leading 
cause of death worldwide and remains the 
foremost cause of preventable death globally. 
The need for more research in the field of 
cardiovascular disease in developing countries is 
underscored by the prevalence of cardiovascular 
disease in all age group of patients in these 
countries. 6-(4-Aminophenyl)-4,5-dihydro-3(2H)-
pyridazinone is an important chemical moiety 
that is useful for the development of cardio-active 
agents. The potential of its derivatives as 
cardioactive agents is evident from the literature 
as reviewed in this article. It is our belief that the 
exploitation of 6-(4-aminophenyl)-4,5-dihydro-
3(2H)-pyridazinone derivatives can produce 
more potent cardio-active agents for  clinical use 
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